Merck ’s Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to Lantus®
< div class= " field field-type-text field-field-press-release-city field-fieldpressreleasecity " > < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " >
KENILWORTH, N.J. < /div > < /div > < /div > < div class= " field field-type-text field-field-press-release-subheadline field-fieldpressreleasesubheadline " > < div class= " field-items " > < div class= " field-item odd " > < p > Data in Patients with Type 1 and Type 2 Diabetes Presented for the First Time at the 76 < sup > th < /sup > Scientific Sessions of the...
Source: Merck.com - Research and Development News - June 13, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK MSD Source Type: news
Merck’s Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to Lantus®
Dateline City:
KENILWORTH, N.J.
Data in Patients with Type 1 and Type 2 Diabetes Presented for the First Time at the 76 th Scientific Sessions of the American Diabetes Association
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada,
today announced results from two Phase 3 studies evaluating MK-1293,
Merck’s investigational, follow-on biologic* insulin glargine candidate
for the treatment of people with t...
Source: Merck.com - Research and Development News - June 13, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK MSD Source Type: news
Basaglar (Basaglar Insulin Glargine Subcutaneous Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 9, 2016 Category: Drugs & Pharmacology Source Type: news
Sanofi T2D Combo Injection Wins FDA Panel Support
(MedPage Today) -- Close to unanimous approval of the insulin glargine/lixisenatide combination (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - May 26, 2016 Category: American Health Source Type: news
UnitedHealthcare Takes Away Diabetes Devices
If you've heard about UnitedHealthcare (UHC) limiting members to only Medtronic insulin pumps beginning July 1 and feel this is wrong, please go to "We are DPAC" (Diabetes Patient Advocacy Coalition) and say so.
UHC members will no longer have an in-network choice among insulin pump providers. UHC has chosen Medtronic as their preferred, in-network durable medical equipment provider of insulin pumps.
The Diabetes Online Community is rallying its social media power and our collective voice to like David, bring down Goliath -- this time in the guise of UnitedHealthcare.
Whether you are a UHC member, or even use an insulin...
Source: Healthy Living - The Huffington Post - May 5, 2016 Category: Consumer Health News Source Type: news
FDA Drug Safety Communication: Update to ongoing safety review of Lantus (insulin glargine) and possible risk of cancer
[1-12-2011] The U.S. Food and Drug Administration (FDA) is updating the public about its ongoing safety review of Lantus (insulin glargine) and a possible increased risk of cancer. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 4, 2016 Category: Drugs & Pharmacology Source Type: news
Biocon's biosimilars progress
Analysts gave a thumbs up to Biocon after the company said its copy of biopharmaceutical insulin glargine met the primary targets, which in effect takes the product closer to regulatory filings in the US. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 29, 2016 Category: Pharmaceuticals Source Type: news
Biocon gets nod to sell its diabetes product 'Insulin Glargine' in Japan
Biocon has received approval from the Japanese health authority to sell its biosimilar product 'Insulin Glargine' in that country. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 28, 2016 Category: Pharmaceuticals Source Type: news
Toujeo (Insulin Glargine Injection for Subcutaneous Use) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 7, 2016 Category: Drugs & Pharmacology Source Type: news
Eli Lilly launches once-a-week diabetes drug in India
The once-a-week non-insulin injectable Trulicity is distinct in the duration of dosage compared to products like Novo Nordisk's Victoza or Sanofi's Lantus. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 3, 2016 Category: Pharmaceuticals Source Type: news
Insulin Degludec/Liraglutide Appears to Outperform Glargine in Type 2 Diabetes (FREE)
By Amy Orciari Herman
Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM
In adults with uncontrolled type 2 diabetes, insulin degludec/liraglutide is noninferior to insulin glargine and may in fact be superior, … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - March 2, 2016 Category: Primary Care Source Type: news
FDA Accepts Sanofi NDA for Once-Daily Fixed-Ratio Combination of Insulin Glargine and Lixisenatide
PARIS, Feb. 22, 2016 /PRNewswire/ -- Sanofi announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for its investigational fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - February 22, 2016 Category: Drugs & Pharmacology Source Type: news
Mike Stout joins Ashfield as CEO, US Commercial and Clinical Businesses
Ivyland, Pennsylvania – 19 February , 2016 – Ashfield Commercial and Medical Services has announced that Mike Stout has joined the company as CEO of its Commercial and Clinical business units (contract sales, nursing and patient support services) in the United States, effective January 11 2016. Located at the company’s national headquarters in Ivyland, Pennsylvania, Mike takes over the role from Nigel Mansford, who will continue with the company in a newly created role after a comprehensive handover. Mike comes to Ashfield from Mylan, where he has been Vice President, Global Commercial and Sales Excellence, since 201...
Source: Ashfield Healthcare News - February 22, 2016 Category: Pharmaceuticals Authors: Josee Leach Tags: Ashfield Source Type: news
ORIGINALE Published: Insulin Glargine Neutral on CVD, CancerORIGINALE Published: Insulin Glargine Neutral on CVD, Cancer
The results of the follow-on trial to ORIGIN have been published and reassure that insulin glargine has neutral effects on cardiovascular outcomes and cancer in patients with dysglycemia or diabetes. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - January 8, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Basaglar (Basaglar Insulin Glargine Subcutaneous Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 26, 2015 Category: Drugs & Pharmacology Source Type: news
